TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT06802081
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT06802081
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06802081. Randomized; triple masking; primary purpose treatment. Start 2025-04-08 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
- Acronym
- TIRO-AF
- Condition
- Atrial Fibrillation
- Condition
- Obesity
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Placebo
- Lead sponsor
- The Cleveland Clinic
Record details
- Record id
cardio:ct-nct06802081- Content hash
2cd7a4b5fceb76ff8a6d5374d140b63ede65203226cab2859c41e6a2d07a50c1